AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. INTS
  4. [8-K] Intensity Therapeutics, Inc. Common stock Reports Material Event

[8-K] Intensity Therapeutics, Inc. Common stock Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Filing content is currently unavailable.

Source:

Stock INTS logo
INTENSITY THERAPEUTICS INC

NASDAQ:INTS

INTS Rankings

#5928 Ranked by Market Cap
N/A Ranked by Dividends

INTS Latest News

Sep 10, 2025
Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update
Sep 2, 2025
Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
Aug 12, 2025
Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
Aug 7, 2025
Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Aug 4, 2025
Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025

INTS Latest SEC Filings

Sep 10, 2025
[8-K] Intensity Therapeutics, Inc. Common stock Reports Material Event
Sep 9, 2025
[DEF 14A] Intensity Therapeutics, Inc. Common stock Definitive Proxy Statement
Aug 28, 2025
[PRE 14A] Intensity Therapeutics, Inc. Common stock Preliminary Proxy Statement
Aug 14, 2025
[SCHEDULE 13G/A] Intensity Therapeutics, Inc. Common stock SEC Filing
Aug 12, 2025
[8-K] Intensity Therapeutics, Inc. Common stock Reports Material Event

INTS Stock Data

13.70M
40.82M
13.25%
4.24%
2.05%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
SHELTON